Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.50 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.48 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395086 | 0.75 | HSD11B1 (0.64) | HSD11B1NR1H2NR1H3MCHR2OXTR | |
| SCHEMBL4554348 | 0.75 | HSD11B1 (0.57) | HSD11B1 | |
| SCHEMBL762618 | 0.71 | MCHR2 (0.58) | HSD11B1NR1H2NR1H3MCHR2OXTR | |
| SCHEMBL4984631 | 0.71 | MCHR2 (0.60) | HSD11B1MCHR2NPC1L1 | |
| SCHEMBL8472020 | 0.70 | OXTR (0.57) | HSD11B1MCHR2OXTR | |
| SCHEMBL4357451 | 0.70 | MCHR2 (0.52) | HSD11B1MCHR2OXTRNPC1L1 | |
| SCHEMBL3839355 | 0.70 | MCHR2 (0.61) | HSD11B1MCHR2NPC1L1 | |
| SCHEMBL2212218 | 0.70 | HSD11B1 (0.47) | HSD11B1 | |
| SCHEMBL12511832 | 0.70 | HSD11B1 (0.47) | HSD11B1 | |
| SCHEMBL8182388 | 0.70 | HSD11B1 (0.47) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501432-B2 | Spiro-piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | claimed |
| US-20080167333-A1 | NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-07-10 | — | — | US | claimed |
| EP-2125726-B1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-07-27 | — | — | EP | disclosed |
| EP-2125726-B1 | SPIRO-PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-7678806-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678806-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678806-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-2125726-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-7501432-B2 | Spiro-piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501432-B2 | Spiro-piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501432-B2 | Spiro-piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080280898-A1 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080167333-A1 | NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080167333-A1 | NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080167333-A1 | NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080161304-A1 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161304-A1 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161304-A1 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008077811-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008077811-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161304-A1 | Spiro-piperidine derivatives | AVPR1A, AVPR1B, ADRA1A | HSD11B1 1386/4885NR1H2 536/4885NR1H3 645/4885 |
| US-20080167333-A1 | NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | HTR1A, HTR5A, ADRA1A | HSD11B1 1815/4885NR1H2 495/4885NR1H3 699/4885 |
| US-20080280898-A1 | Spiro-piperidine derivatives | AVPR1A, AVPR1B, ADRA1A | HSD11B1 1386/4885NR1H2 536/4885NR1H3 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.